Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Enriqueta Felip et al.|New England Journal of Medicine|2020Cited by 879
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Ihor Vynnychenko, Oleksandr Goloborodko et al.|Journal of Clinical Oncology|2025Cited by 44
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Heather A. Wakelee, Enriqueta Felip, Nasser K. Altorki et al.|Journal of Clinical Oncology|2024Cited by 22